- Report of Foreign Issuer (6-K)
October 28 2008 - 7:05AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
27 October 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into
English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange
Act of 1934.
Yes
No
X
If “Yes” is marked, indicate below the
file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
The Registrant is furnishing a copy of its
announcements as reported to the Company Announcements Office of the London Stock
Exchange.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROTHERICS PLC
|
|
|
|
|
|
|
|
|
|
Date: 27 October 2008
|
|
By:
|
|
/s/ Rolf Soderstrom
|
|
|
|
|
|
Rolf Soderstrom
|
|
|
|
|
|
Finance Director
|
Protherics PLC
Notification of Major Interests in
Shares
London, UK; Brentwood, TN, US: 27
October 2008 -
Protherics PLC ("Protherics" or the "Company"), the
international biopharmaceutical company focused on critical care and cancer,
announces that on 27 October 2008, in accordance with the Transparency
Obligations Directive, a notification of interest in the ordinary share
capital of the Company was received from AXA Investment
Managers UK Limited on behalf of AXA S.A. and its Group
Companies ("AXA"). Details of the interest notified are set out below.
The notification follows an increase in the Company's issued ordinary
share capital following the conversion of all outstanding six per cent. unsecured
convertible loan notes 2010 of Protherics, as further described in the announcement made
jointly by Protherics and BTG plc on 18 September 2008.
|
1. Reason for
the notification
(please tick the
appropriate
box or
boxes)
|
|
|
An acquisition or disposal of voting rights
|
|
|
An acquisition or disposal of financial instruments which may
result in the acquisition of shares already issued to which voting rights are
attached
|
|
|
An event changing the breakdown of voting rights
|
|
|
Other (please specify):
variation in issued share
capital
|
X
|
|
2. Full name of person(s) subject to the notification
obligation:
|
AXA S.A., 25 Avenue Matignon, 75008 Paris and its group of
companies.
|
|
3. Full name of shareholder(s) (if different from 2.):
|
|
|
4. Date of the transaction (and date on which the threshold is
crossed or reached if different):
|
26 October 2008
|
|
5. Date on which issuer notified:
|
27 October 2008
|
|
6. Threshold(s) that is/are crossed or reached:
|
12%
|
|
|
|
7. Notified details:
|
|
A: Voting rights attached to shares
|
|
Class/type of
shares
if possible using the ISIN CODE
|
Situation previous to the Triggering
transaction
|
Resulting situation after the triggering
transaction
|
|
Number of
Shares
|
Number of Voting
Rights
|
Number of shares
|
Number of voting
rights
|
% of voting rights
|
|
Direct
|
Direct
|
Indirect
|
Direct
|
Indirect
|
|
0702920
|
42,026,712
|
42,026,712
|
1,041,666
|
1,041,666
|
40,985,046
|
0.30%
|
11.70 %
|
|
B: Financial Instruments
|
|
Resulting situation after the triggering
transaction
|
|
Type of financial
instrument
|
Expiration date
|
Exercise/ Conversion Period/
Date
|
Number of voting rights that may be
acquired if the instrument is exercised/ converted.
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total (A+B)
|
|
Number of voting
rights
|
% of voting rights
|
|
42,026,712
|
11.99%
|
|
8. Chain of controlled undertakings through which the
voting rights and/or the financial instruments are effectively held, if
applicable :
|
|
Name of Company/Fund
|
Number of Shares
|
% of issued share
capital
|
|
AXA
Direct
|
716,666
|
|
0.20451
|
|
|
AXA Framlington
Indirect
|
40,985,046
|
|
11.69573
|
|
|
AXA IM UK
Direct
|
325,000
|
|
0.09274
|
|
|
Total Direct
Total Indirect
|
1,041,666
40,985,046
|
|
0.29726
11.69573
|
|
|
TOTAL
|
42,026,712
|
|
11.99298
|
|
|
|
|
Proxy Voting:
|
|
9. Name of the proxy holder:
|
|
|
10. Number of voting rights proxy holder will cease to hold:
|
|
|
11. Date on which proxy holder will cease to hold
voting rights:
|
|
|
12. Additional information:
|
|
| Ends |
For further information please contact:
|
Protherics
|
|
|
Nick Staples, Director of Corporate Affairs
|
+44 (0) 7919 480510
|
|
Julie Vickers, Company Secretary
|
+44 (0)1928 518010
|
|
|
|
|
Financial Dynamics
- press enquiries
|
|
|
London: Ben Atwell, Lara Mott
|
+44 (0) 20 7831 3113
|
|
New York: John Capodanno
|
+1 212 850 5600
|
Or visit
www.protherics.com
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jul 2023 to Jul 2024
